Molecular Diagnostic Applications in Colorectal Cancer

Colorectal cancer, a clinically diverse disease, is a leading cause of cancer-related death worldwide. Application of novel molecular diagnostic tests, which are summarized in this article, may lead to an improved survival of colorectal cancer patients. Distinction of these applications is based on the different molecular principles found in colorectal cancer (CRC). Strategies for molecular analysis of single genes (as KRAS or TP53) as well as microarray based techniques are discussed. Moreover, in addition to the fecal occult blood testing (FOBT) and colonoscopy some novel assays offer approaches for early detection of colorectal cancer like the multitarget stool DNA test or the blood-based Septin 9 DNA methylation test. Liquid biopsy analysis may also exhibit great diagnostic potential in CRC for monitoring developing resistance to treatment. These new diagnostic tools and the definition of molecular biomarkers in CRC will improve early detection and targeted therapy of colorectal cancer.

[1]  A. Culyer.  Proof of Principle , 2014 .

[2]  D. Ransohoff,et al.  Multitarget stool DNA testing for colorectal-cancer screening. , 2014, The New England journal of medicine.

[3]  Y. Bignon,et al.  MicroRNAs 146a and 147b Biomarkers for Colorectal Tumor's Localization , 2014, BioMed research international.

[4]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[5]  J. Hurley,et al.  The molecular genetics of colorectal cancer , 2013, Frontline Gastroenterology.

[6]  J. Hornick,et al.  Immunohistochemistry using the BRAF V600E mutation‐specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma , 2013, Histopathology.

[7]  S. Varma,et al.  Toward a comprehensive and systematic methylome signature in colorectal cancers , 2013, Epigenetics.

[8]  A. Glas,et al.  Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer , 2013, Annals of surgery.

[9]  Jun Yu,et al.  Tumor Suppressor Functions of miR-133a in Colorectal Cancer , 2013, Molecular Cancer Research.

[10]  P. Vos,et al.  Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. , 2013, Cancer genomics & proteomics.

[11]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[12]  Florian Markowetz,et al.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions , 2013, Nature Medicine.

[13]  R. Vyzula,et al.  MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients , 2012, Radiation oncology.

[14]  Vasyl Pihur,et al.  Gene expression anti-profiles as a basis for accurate universal cancer signatures , 2012, BMC Bioinformatics.

[15]  Sabine Tejpar,et al.  A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency# , 2012, The Journal of pathology.

[16]  H. Brenner,et al.  A novel multiplex-protein array for serum diagnostics of colon cancer: a case–control study , 2012, BMC Cancer.

[17]  P. Vos,et al.  Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. , 2012, Cancer genomics & proteomics.

[18]  O. Nordgård,et al.  Comparison of a PNA Clamp PCR and an ARMS/Scorpion PCR Assay for the Detection of K-ras Mutations , 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[19]  M. Marzo,et al.  Knowledge and attitudes of primary healthcare patients regarding population-based screening for colorectal cancer , 2011, BMC Cancer.

[20]  S. Poulsen,et al.  Seromic profiling of colorectal cancer patients with novel glycopeptide microarray , 2011, International Journal of Cancer.

[21]  A. V. D. van den Brule,et al.  SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. , 2011, The Journal of molecular diagnostics : JMD.

[22]  C. Mayer,et al.  Custom design of a GeXP multiplexed assay used to assess expression profiles of inflammatory gene targets in normal colon, polyp, and tumor tissue. , 2011, The Journal of molecular diagnostics : JMD.

[23]  F. Cianchi,et al.  The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. , 2010, The Journal of molecular diagnostics : JMD.

[24]  J. Neumann,et al.  Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. , 2009, Pathology, research and practice.

[25]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[26]  C. Pilarsky,et al.  Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay , 2008, PloS one.

[27]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[28]  W. Grady,et al.  Genomic and epigenetic instability in colorectal cancer pathogenesis. , 2008, Gastroenterology.

[29]  Frank J. Sørensen,et al.  Diagnostic and prognostic microRNAs in stage II colon cancer. , 2008, Cancer research.

[30]  B. Wolpin,et al.  Systemic treatment of colorectal cancer. , 2008, Gastroenterology.

[31]  M Westwood,et al.  Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review , 2007, Journal of medical screening.

[32]  S. Benlloch,et al.  Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. , 2006, The Journal of molecular diagnostics : JMD.

[33]  R. Gafà,et al.  Microsatellite Instability and Colorectal Cancer Prognosis , 2005, Clinical Cancer Research.

[34]  Roisin M Molloy,et al.  Automation of biochip array technology for quality results , 2005, Clinical chemistry and laboratory medicine.

[35]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[36]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[37]  S. Asai,et al.  Clinical Application of Oligonucleotide Probe Array for Full-Length Gene Sequencing of TP53 in Colon Cancer , 2002, Oncology.

[38]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[39]  Bruno Landi,et al.  Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis , 2002, International journal of cancer.

[40]  M. White,et al.  Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. , 2000, Cancer research.

[41]  J. Jen,et al.  Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  V. Velculescu,et al.  Biological and clinical importance of the p53 tumor suppressor gene. , 1996, Clinical chemistry.

[43]  F. Bizouarn,et al.  Clinical applications using digital PCR. , 2014, Methods in molecular biology.

[44]  L. V. van't Veer,et al.  Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[46]  M. Hollstein,et al.  Clinical implications of the p53 gene. , 1996, Annual review of medicine.

[47]  M. Barbacid.  ras genes. , 1987, Annual review of biochemistry.